权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting_the_Source_of_Persistent_HIV_Viremia

持续性 HIV 病毒血症的目标来源

基本信息

批准号：
8047422
负责人：
Sarah Elizabeth Palmer
金额：
$ 25.03万
依托单位：
KAROLINSKA INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-04-15 至 2012-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8047422
关键词：
AIDS/HIV problem Academic Medical Centers Address Aftercare Animal Model Animals Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Biological Assay Blood Cells Bone Marrow CD4 Positive T Lymphocytes California Cell Lineage Cells Cerebrospinal Fluid Clinical Research Clinical Treatment Clinical Trials Communicable Diseases DNA Methylation DNA Sequence Disease Management Europe Funding Future Gene Activation General Hospitals Genetic Genetic Transcription Genome Goals Gut associated lymphoid tissue HIV HIV Infections HIV therapy HIV-1 Histone Deacetylation Human Immune In Vitro Infection Institutes Institution Knowledge Label Life Ligation Lymph Node Tissue Macaca Measures Mediating Medical Research Memory Methods Methylation Modeling Molecular Molecular Genetics Netherlands Neuraxis Neurology Patients Pharmaceutical Preparations Pharmacologic Substance Pharmacotherapy Phylogenetic Analysis Plasma Plasma Cells Population Population Genetics Principal Investigator Production Publishing Peer Reviews RNA RNA Sequences Regimen Reporting Research Research Personnel Residual state San Francisco Signal Transduction Site Source Surface T memory cell Techniques Testing Therapeutic Tissues Translational Research Treatment Protocols United States Universities Viral Viremia Virion Virus Work antiretroviral therapy base cell type disorder control drug development drug testing effective therapy efficacy testing genome sequencing in vivo inhibitor/antagonist killings memory CD4 T lymphocyte particle peripheral blood prevent programs success tool transcription factor viral DNA viral RNA

项目摘要

Current antiretroviral therapy is not curative and does not eradicate HIV-1 viremia. Rather, the virus persists and is merely suppressed during therapy. The source and dynamics of this persistent viremia is currently unknown. Determining the source of persistent viremia during combination antiretroviral therapy will inform future efforts aimed at viral eradication. To address these important issues the current study puts forward two hypotheses. First, to identify the source of persistent viremia in patients on suppressive therapy we must compare HIV populations in patient plasma to the HIV populations found in the cerebrospinal fluid (CSF), cells from peripheral blood and cells isolated from other tissues. Second, activating the latently HIV-infected cell will induce the expression of the integrated HIV genome making it vulnerable to immune-mediated killing and therapy. To test these hypotheses we seek to achieve three specific aims. First, we will characterize the HIV-1 genetic populations in plasma, CSF and a broad spectrum of HIV-infected cells from peripheral blood, gut associated lymphoid tissue (GALT), lymph node tissue (LNT), and bone marrow tissue (BMT) from patients on suppressive therapy using such methods as single-genome sequencing and single-proviral sequencing. The phylogenetic relatedness of the plasma-derived viral RNA sequences and intracellular viral DNA sequences will be determined. The comparison of HIV populations from plasma to different cellular and tissue compartments will allow us to investigate and seek to identify the source and genetic dynamics of persistent viremia in patients on suppressive therapy. For our second aim, we will apply peer-reviewed and published ligation-based molecular tools known as proximity ligation probes to specifically label and measure HIV virions and identify the cellular source of these particles. This will be important for identifying the cell lineage producing virions during suppressive therapy. Third, we will use new inhibitors of DNA methylation, protein methylation or histone deacetylation to stimulate cellular HIV transcription and therefore release of HIV from latently infected memory CD4+ T-cells, making the virus vulnerable to antiretroviral drugs. To accomplish this aim, we will culture CD4+ memory T-cells from patients on suppressive therapy and expose these cells to the new inhibitors. This research plan will bring together a diverse, multinational group of experts from Europe and United States specializing in HIV translational research, HIV clinical treatment, molecular genetics, and antiviral drug development.

目前的抗逆转录病毒疗法不能治愈，也不能根除HIV-1病毒血症。相反，病毒会持续存在